DrugPatentWatch Database Preview
CEFADROXIL Drug Profile
Which patents cover Cefadroxil, and when can generic versions of Cefadroxil launch?
Cefadroxil is a drug marketed by Aurobindo Pharma, Cspc Ouyi, Hikma, Ivax Sub Teva Pharms, Lupin, Orchid Hlthcare, Purepac Pharm, Ranbaxy Labs Ltd, Sandoz, Teva, Teva Pharms, Ani Pharms Inc, Apothecon, Aurobindo, Hikma Pharms, Sun Pharm Inds Ltd, and Ranbaxy. and is included in twenty-three NDAs.
The generic ingredient in CEFADROXIL is cefadroxil/cefadroxil hemihydrate. Twenty-six suppliers are listed for this compound. Additional details are available on the cefadroxil/cefadroxil hemihydrate profile page.
Summary for CEFADROXIL
| US Patents: | 0 |
| Applicants: | 17 |
| NDAs: | 23 |
| Suppliers / Packagers: | 26 |
| Bulk Api Vendors: | 48 |
| Clinical Trials: | 8 |
| Patent Applications: | 3,714 |
| Drug Prices: | Drug price information for CEFADROXIL |
| DailyMed Link: | CEFADROXIL at DailyMed |
Pharmacology for CEFADROXIL
| Drug Class | Cephalosporin Antibacterial |
Synonyms for CEFADROXIL
| (6R,7R)-7-((R)-2-amino-2-(4-hydroxyphenyl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| (6R,7R)-7-((R)-2-Amino-2-(p-hydroxyphenyl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid |
| (6R,7R)-7-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| (7R)-7-((R)-2-amino-2-(4-hydroxyphenyl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2R)-amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6R,7R)- |
| 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6R-(6-alpha,7-beta(R*)))- |
| 50370-12-2 |
| 592C878 |
| 66592-87-8 |
| 7-[(2R)-2-amino-2-(4-hydroxyphenyl)acetylamino](7R,7aR)-3-methyl-6-oxo-2H,7H-a zetidino[2,1-b]1,3-thiazine-4-carboxylic acid |
| 7beta-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3-methyl-3,4-didehydrocepham-4-carboxylic acid |
| AB00513838 |
| AC1L2J3O |
| AKOS005622555 |
| API0006601 |
| AS-11655 |
| BBL033696 |
| BDBM50350467 |
| BL-S578 |
| BOEGTKLJZSQCCD-UEKVPHQBSA-N |
| BPBio1_000494 |
| BSPBio_000448 |
| C06878 |
| C16H17N3O5S |
| CAS-50370-12-2 |
| CCG-220434 |
| CDX |
| Cefadrops |
| Cefadroxil (JP17) |
| Cefadroxil [INN] |
| Cefadroxil anhydrous |
| Cefadroxil monohydrate, Antibiotic for Culture Media Use Only |
| Cefadroxil, 95-105% |
| Cefadroxil, analytical standard |
| Cefadroxil, Anhydrous |
| CEFADROXIL/CEFADROXIL HEMIHYDRATE |
| Cefadroxilo |
| Cefadroxilo [INN-Spanish] |
| Cefadroxilum |
| Cefadroxilum [INN-Latin] |
| Cefradroxil |
| Cephadroxil |
| CHEBI:3479 |
| CHEMBL1644 |
| CS-4696 |
| CTK8F8512 |
| D-Cefadroxil |
| D00257 |
| DB01140 |
| DivK1c_000409 |
| DSSTox_CID_2749 |
| DSSTox_GSID_22749 |
| DSSTox_RID_76714 |
| DTXSID8022749 |
| Duricef |
| EINECS 256-555-6 |
| Epitope ID:117131 |
| FT-0603067 |
| GTPL4831 |
| HMS1569G10 |
| HMS2096G10 |
| HMS3713G10 |
| HMS501E11 |
| HY-B1190 |
| I04-8441 |
| IDI1_000409 |
| KBio1_000409 |
| KBio2_000544 |
| KBio2_003112 |
| KBio2_005680 |
| KBioGR_000732 |
| KBioSS_000544 |
| MCULE-6475996520 |
| MJF-11567-3 |
| MLS002207219 |
| MolPort-002-507-346 |
| NCGC00016858-01 |
| NCGC00179556-01 |
| NCGC00179556-03 |
| NINDS_000409 |
| NSC-756664 |
| NSC756664 |
| p-Hydroxycephalexine |
| Pharmakon1600-01500163 |
| Prestwick0_000434 |
| Prestwick1_000434 |
| Prestwick2_000434 |
| Prestwick3_000434 |
| Q525PA8JJB |
| S 578 |
| S-578 |
| SBI-0051305.P003 |
| SC-74593 |
| SCHEMBL151320 |
| SMR001306770 |
| SPBio_000014 |
| SPBio_002387 |
| Spectrum_000104 |
| Spectrum2_000087 |
| Spectrum4_000266 |
| Spectrum5_000663 |
| ST51014960 |
| STK801939 |
| Sumacef (TN) |
| Tox21_110651 |
| Tox21_110651_1 |
| Ultracef |
| UNII-Q525PA8JJB |
| ZINC3830391 |
US Patents and Regulatory Information for CEFADROXIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Orchid Hlthcare | CEFADROXIL | cefadroxil/cefadroxil hemihydrate | TABLET;ORAL | 065301-001 | Sep 18, 2006 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Sun Pharm Inds Ltd | CEFADROXIL | cefadroxil/cefadroxil hemihydrate | FOR SUSPENSION;ORAL | 065115-001 | Mar 26, 2003 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Ranbaxy | CEFADROXIL | cefadroxil/cefadroxil hemihydrate | TABLET;ORAL | 065018-001 | Apr 23, 1999 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Sun Pharm Inds Ltd | CEFADROXIL | cefadroxil/cefadroxil hemihydrate | FOR SUSPENSION;ORAL | 065115-002 | Mar 26, 2003 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
